✨ Your Portfolio is fetched and updated from zerodha.
Micro Pharmaceuticals

Emmessar Biotech & Nutrition Ltd.

EMMESSA

Market Cap
₹20 Cr.
P/E
63.18

Emmessar Biotech & Nutrition Ltd.

  • Emmessar Biotech&Nut
  • Hamps Bio
  • Parmax Pharma
FAQs on Emmessar Biotech & Nutrition Ltd. Shareprice

Emmessar Biotech&Nut has given lower returns compared to its competitors.
Emmessar Biotech&Nut has grown at ~-4.17% over the last 1yrs while peers have grown at a median rate of 14.0%

Emmessar Biotech&Nut is expensive when considering the PE ratio, however latest EV/EBIDTA is < 3 yr avg EV/EBIDTA.
Latest PE of Emmessar Biotech&Nut is 24.07, while 3 year average PE is 22.68.
Also latest EV/EBITDA of Emmessar Biotech&Nut is 0.0 while 3yr average is 5.81.

View FAQ's On Business
Growth Table
  • Emmessar Biotech & Nutrition Ltd.
  • Hamps Bio
  • Parmax Pharma
Balance Sheet
  • Emmessar Biotech & Nutrition Ltd.
  • Hamps Bio
  • Parmax Pharma
Balance Sheet Snapshot
No data available.
Fund Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end
Profit & Loss
  • Emmessar Biotech & Nutrition Ltd.
  • Hamps Bio
  • Parmax Pharma
Cash Flow
  • Emmessar Biotech & Nutrition Ltd.
  • Hamps Bio
  • Parmax Pharma
Cash Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
Ratios
= Dominant Factor
  • Emmessar Biotech & Nutrition Ltd.
  • Hamps Bio
  • Parmax Pharma
Quarterly Results
  • Emmessar Biotech & Nutrition Ltd.
  • Hamps Bio
  • Parmax Pharma
Reverse DCF
locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Rhapson method.
Learn how to use Reverse DCF
FAQs on Emmessar Biotech & Nutrition Ltd. Financials

Balance sheet of Emmessar Biotech&Nut is strong.
It shouldn't have solvency or liquidity issues.

Yes, The debt of Emmessar Biotech&Nut is increasing.
Latest debt of Emmessar Biotech&Nut is -₹6.64 Crs as of Sep-24.
This is greater than Mar-24 when it was -₹12.26 Crs.

Yes, profit is increasing.
The profit of Emmessar Biotech&Nut is ₹0.76 Crs for TTM, ₹0.75 Crs for Mar 2024 and ₹0.5 Crs for Mar 2023.

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Emmessar Biotech&Nut latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%

Companies resources are allocated to majorly unproductive assets like Cash & Short Term Investments

View FAQ's On Shareholding
Ideas Dashboard
Timeline
Watchlist
Portfolio
Alerts
Research
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech